摘要
目的探讨双歧三联活菌联合三联疗法对治疗慢性胃炎的临床疗效。方法选取入我院就诊的诊断为Hp阳性的慢性胃炎患者共62例,随机分为观察组(32例)和对照组(30例),对照组患者予以奥美拉唑+阿莫西林分散片+克拉霉素三联疗法治疗。观察组在对照组的基础上予以双歧杆菌三联活菌胶囊。两组治疗疗程均为14 d,停药4周后行14C呼气实验复查幽门螺杆菌,同时判断两组患者的临床症状。结果观察组患者临床症状评分低于对照(P<0.05),观察组的根除率(90.6%),高于对照组(83.3%)(P<0.05)。结论双歧杆菌三联活菌联合三联疗法能够显著改善患者的临床症状,提高了Hp的根除率。
Objective To explore the clinical efficacy of Bifid Triple Viable combined with triple therapy in the treatment of chronic gastritis. Methods The diagnosis were selected in our hospital for treatment of Hp positive thronic gastritis patients with a total of 62 cases were randomly divided into observation group （32 cases） and control group （30 cases）, the control group was treated with omeprazole ＋ Amoxicillin Dispersible Tablets ＋ clarithromycin triple therapy. The observation group in the control group treated with Bifid Triple Viable capsule. Two groups of treatment were 14 days, 4 weeks after discontinuation of 14C breath test review of Helicobacter pylori, and determine the clinical symptoms of the two groups. Results The clinical symptom score of the observation group was significantly lower than that of the control group （P 〈 0.05）. The eradication rate of the observation group （90.6%） was significantly higher than that of the control group （83.3%） （P 〈 0.05） Conclusion Bifidobacterium triple viable combined with triple therapy can significantly improve the clinical symptoms of patients, improve the eradication rate of Hp.
出处
《中国继续医学教育》
2017年第10期171-172,共2页
China Continuing Medical Education
关键词
双歧杆菌
三联活菌
三联疗法
慢性胃炎
bifidobacterium
triple viable
triple therapy
chronic gastritis
